The immunotherapy of Guillain-Barré syndrome

References

• Goodfellow JA, Willison HJ. Guillain-Barré syndrome: a century of progress. Nat Rev Neurol. 2016;12:723–731.
   PubMed Web of Science ®Google Scholar
• McGrogan A, Madle GC, Seaman HE, et al. The epidemiology of Guillain-Barré syndrome worldwide. Neuroepidemiology. 2009;32:150–163.
   PubMed Web of Science ®Google Scholar
• Wijdicks EFM, Klein CJ. Guillain-Barré syndrome. Mayo Clin Proc. 2017;92:467–479.
   PubMed Web of Science ®Google Scholar
• Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388:717–727.
   PubMed Web of Science ®Google Scholar
• Mahecha MP, Ojeda E, Vega DA, et al. Guillain-Barré syndrome in Colombia: where do we stand now? Immunol Res. 2017;65:72–81.
   PubMed Web of Science ®Google Scholar
• Yuki N, Hartung H-P. Guillain-Barré syndrome. N Engl J Med. 2012;366:2294–2304.
   PubMed Web of Science ®Google Scholar
• Guerra C, Uribe CS, Guerra A, et al. [Bickerstaff brain encephalitis: case report and literature review]. Biomedica. 2013;33:513–518.
   PubMed Web of Science ®Google Scholar
• Br W, Kokubun N, Funakoshi K, et al. Clinical classification of 103 Japanese patients with Guillain-Barré syndrome. J Neurol Sci. 2016;369:43–47.
   PubMed Web of Science ®Google Scholar
• Walgaard C, Jacobs BC, van Doorn PA. Emerging drugs for Guillain-Barré syndrome. Expert Opin Emerg Drugs. 2011;16:105–120.
   PubMed Web of Science ®Google Scholar
• Wakerley BR, Yuki N. Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2014;85:339–344.
   PubMed Web of Science ®Google Scholar
• Wakerley BR, Yuki N. Mimics and chameleons in Guillain-Barré and miller fisher syndromes. Pract Neurol. 2015;15:90–99.
   PubMedGoogle Scholar
• Yako K, Kusunoki S, Kanazawa I. Serum antibody against a peripheral nerve myelin ganglioside, LM1, in Guillain-Barré syndrome. J Neurol Sci. 1999;168:85–89.
   PubMed Web of Science ®Google Scholar
• Willison HJ. The immunobiology of Guillain-Barré syndromes. J Peripher Nerv Syst. 2005;10:94–112.
   PubMed Web of Science ®Google Scholar
• Kaida K, Ariga T, Yu RK. Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders–a review. Glycobiology. 2009;19:676–692.
   PubMed Web of Science ®Google Scholar
• van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7:939–950.
   PubMed Web of Science ®Google Scholar
• Xiao J, Simard AR, Shi F-D, et al. New strategies in the management of Guillain-Barré syndrome. Clin Rev Allergy Immunol. 2013;47:274–288.
   Web of Science ®Google Scholar
• Kimachi T, Yuki N, Kokubun N, et al. Paraparetic Guillain-Barré syndrome: nondemyelinating reversible conduction failure restricted to the lower limbs. Muscle Nerve. 2017;55:281–285.
   PubMed Web of Science ®Google Scholar
• Zhang G, Li Q, Zhang R, et al. Subtypes and prognosis of Guillain-Barré Syndrome in Southwest China. PLoS One. 2015;10:e0133520.
   PubMed Web of Science ®Google Scholar
• Pfeiffer G. [Dysautonomia in Guillain-Barré syndrome]. Nervenarzt. 1999;70:136–148.
   PubMed Web of Science ®Google Scholar
• Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol. 2010;67:781–787.
   PubMed Web of Science ®Google Scholar
• Overell JR, Hsieh ST, Odaka M, et al. Treatment for Fisher syndrome, Bickerstaff’s brainstem encephalitis and related disorders. Cochrane Database Syst Rev. 2007;1:CD004761.
   PubMed Web of Science ®Google Scholar
• Bayry J, Misra N, Latry V, et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Transfus Clin Biol. 2003;10:165–169.
   PubMed Web of Science ®Google Scholar
• Durandy A, Kaveri SV, Kuijpers TW, et al. Intravenous immunoglobulins–understanding properties and mechanisms. Clin Exp Immunol. 2009;158(Suppl):2–13.
   PubMedGoogle Scholar
• Lehmann HC, Hartung H-P. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. J Neuroimmunol. 2011;231:61–69.
   PubMed Web of Science ®Google Scholar
• Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2012;7:CD002063.
   PubMed Web of Science ®Google Scholar
• Jacobs BC, O’Hanlon GM, Bullens RWM, et al. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain. 2003;126:2220–2234.
   PubMed Web of Science ®Google Scholar
• van Der Meché FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med. 1992;326:1123–1129.
   PubMed Web of Science ®Google Scholar
• Bril V, Ilse WK, Pearce R, et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology. 1996;46:100–103.
   PubMed Web of Science ®Google Scholar
• Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet. 1997;349:225–230.
   PubMed Web of Science ®Google Scholar
• Diener HC, Haupt WF, Kloss TM, et al. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome. Eur Neurol. 2001;46:107–109.
   PubMed Web of Science ®Google Scholar
• Korinthenberg R, Schessl J, Kirschner J, et al. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics. 2005;116:8–14.
   PubMed Web of Science ®Google Scholar
• Yata J, Nihei K, Ohya T, et al. High-dose immunoglobulin therapy for Guillain-Barré syndrome in Japanese children. Pediatr Int. 2003;45:543–549.
   PubMed Web of Science ®Google Scholar
• Fergusson D, Hutton B, Sharma M, et al. Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review. Transfusion. 2005;45:1640–1657.
   PubMed Web of Science ®Google Scholar
• Verboon C, Van Den Berg B, Cornblath D, et al. International second immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (I-SID GBS), a prospective observational study. J Peripher Nerv Syst. 2017;22:226–414.
   Web of Science ®Google Scholar
• Ortiz-Salas P, Velez-Van-Meerbeke A, Galvis-Gomez CA, et al. Human immunoglobulin versus plasmapheresis in guillain-barre syndrome and myasthenia gravis: A Meta-Analysis. J Clin Neuromuscul Dis. 2016;18:1–11.
   PubMedGoogle Scholar
• Kieseier BC, Meyer Zu Hörste G, Hc L, et al. Intravenous immunoglobulins in the treatment of immune neuropathies. Curr Opin Neurol. 2008;21:555–562.
   PubMed Web of Science ®Google Scholar
• Lehmann HC, Meyer Zu Horste G, Bc K, et al. Pathogenesis and treatment of immune-mediated neuropathies. Ther Adv Neurol Disord. 2009;2:261–281.
   PubMedGoogle Scholar
• Lu M-O, Zhu J. The role of cytokines in Guillain-Barré syndrome. J Neurol. 2011;258:533–548.
   PubMed Web of Science ®Google Scholar
• Jasti AK, Selmi C, Sarmiento-Monroy JC, et al. Guillain-Barré syndrome: causes, immunopathogenic mechanisms and treatment. Expert Rev Clin Immunol. 2016;12:1175–1189.
   PubMed Web of Science ®Google Scholar
• Hartung HP, Pollard JD, Harvey GK, et al. Immunopathogenesis and treatment of the Guillain-Barré syndrome–part II. Muscle Nerve. 1995;18:154–164.
   PubMedGoogle Scholar
• Bouget J, Chevret S, Chastang C, et al. Plasma exchange morbidity in Guillain-Barré syndrome: results from the French prospective, randomized, multicenter study. The French cooperative group. Crit Care Med. 1993;21:651–658.
   PubMedGoogle Scholar
• Shahrizaila N, Yuki N. The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of action. Expert Opin Pharmacother. 2011;12:1551–1560.
   PubMed Web of Science ®Google Scholar
• Greenwood RJ, Newsom-Davis J, Hughes RA, et al. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet. 1984;1:877–879.
   PubMed Web of Science ®Google Scholar
• Mendell JR, Kissel JT, Kennedy MS, et al. Plasma exchange and prednisone in Guillain-Barré syndrome: a controlled randomized trial. Neurology. 1985;35:1551–1555.
   PubMed Web of Science ®Google Scholar
• Raphael JC, Chevret S, Auriant I, et al. Treatment of the adult Guillain-Barré syndrome: indications for plasma exchange. Transfus Sci. 1999;20:53–61.
   PubMedGoogle Scholar
• Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2017;2:CD001798.
   PubMedGoogle Scholar
• Wollinsky KH, Hülser PJ, Brinkmeier H, et al. CSF filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial. Neurology. 2001;57:774–780.
   PubMed Web of Science ®Google Scholar
• Wollinsky KH, Hülser PJ, Westarp ME, et al. Cerebrospinal fluid pheresis in Guillain Barré syndrome. Med Hypotheses. 1992;38:155–165.
   PubMed Web of Science ®Google Scholar
• Wollinsky KH, Weindler M, Hülser PJ, et al. Liquorpheresis (CSF-filtration): an effective treatment in acute and chronic severe autoimmune polyradiculoneuritis (Guillain-Barré syndrome). Eur Arch Psychiatry Clin Neurosci. 1991;241:73–76.
   PubMed Web of Science ®Google Scholar
• Randall DP. Treatment of Guillain-Barré Syndrome. Disease-a-Month. 2010;56:279–287.
   Web of Science ®Google Scholar
• Wang Y-Z, Lv H, Shi Q-G, et al. Action mechanism of corticosteroids to aggravate Guillain-Barré syndrome. Sci Rep. 2015;5:13931.
   PubMed Web of Science ®Google Scholar
• Meyer zu Hörste G, Hartung H-P, Kieseier BC. From bench to bedside–experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol. 2007;3:198–211.
   PubMedGoogle Scholar
• Haass A, Trabert W, Gressnich N, et al. High-dose steroid therapy in Guillain-Barré syndrome. J Neuroimmunol. 1988;20:305–308.
   PubMed Web of Science ®Google Scholar
• Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:195–201.
   PubMed Web of Science ®Google Scholar
• Goodall JA, Kosmidis JC, Geddes AM. Effect of corticosteroids on course of Guillain-Barré syndrome. Lancet. 1974;1:524–526.
   PubMed Web of Science ®Google Scholar
• Rajabally YA. Treatment of Guillain-Barré syndrome: a review. Inflamm Allergy Drug Targets. 2012;11:330–334.
   PubMedGoogle Scholar
• Hughes RA, Newsom-Davis JM, Perkin GD, et al. Controlled trial prednisolone in acute polyneuropathy. Lancet. 1978;2:750–753.
   PubMed Web of Science ®Google Scholar
• Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet. 1993;341:586–590.
   PubMed Web of Science ®Google Scholar
• van Koningsveld R, Schmitz PIM, Meché FGA, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet. 2004;363:192–196.
   PubMed Web of Science ®Google Scholar
• Hughes RAC. Systematic reviews of treatment for inflammatory demyelinating neuropathy. J Anat. 2002;200:331–339.
   PubMed Web of Science ®Google Scholar
• Hughes RAC, Swan AV, Raphaël J-C, et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain. 2007;130:2245–2257.
   PubMed Web of Science ®Google Scholar
• Hughes RA, Brassington R, Gunn AA, et al. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2016;10:CD001446.
   PubMed Web of Science ®Google Scholar
• Kaida K, Kusunoki S. Guillain-Barré syndrome: update on immunobiology and treatment. Expert Rev Neurother. 2009;9:1307–1319.
   PubMed Web of Science ®Google Scholar
• Pilch KS, Spaeth PJ, Yuki N, et al. Therapeutic complement inhibition: a promising approach for treatment of neuroimmunological diseases. Expert Rev Neurother. 2017;17:579–591.
   PubMed Web of Science ®Google Scholar
• Halstead SK, Humphreys PD, Zitman FMP, et al. C5 inhibitor rEV576 protects against neural injury in an in vitro mouse model of Miller Fisher syndrome. J Peripher Nerv Syst. 2008;13:228–235.
   PubMed Web of Science ®Google Scholar
• Halstead SK, Zitman FMP, Humphreys PD, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain. 2008;131:1197–1208.
   PubMed Web of Science ®Google Scholar
• Davidson AI, Halstead SK, Goodfellow JA, et al. Inhibition of complement in Guillain-Barré syndrome: the ICA-GBS study. J Peripher Nerv Syst. 2017;22:4–12.
   PubMed Web of Science ®Google Scholar
• JET-GBS - Japanese Eculizumab Trial for GBS - Full Text View - ClinicalTrials.gov. [Internet]. [ cited Date 2017 Oct 30]. Accessed on April 24, 2018,  Available from: https://clinicaltrials.gov/ct2/show/NCT02493725
   Google Scholar
• Hepburn NJ, Williams AS, Nunn MA, et al. In vivo characterization and therapeutic efficacy of a C5-specific inhibitor from the soft tick ornithodoros moubata. J Biol Chem. 2007;282:8292–8299.
   PubMed Web of Science ®Google Scholar
• Phongsisay V, Susuki K, Matsuno K, et al. Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barré syndrome. J Neuroimmunol. 2008;205:101–104.
   PubMed Web of Science ®Google Scholar
• Halstead SK, Humphreys PD, Goodfellow JA, et al. Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome. Ann Neurol. 2005;58:203–210.
   PubMed Web of Science ®Google Scholar
• Danielsson C, Pascual M, French L, et al. Soluble complement receptor type 1 (CD35) is released from leukocytes by surface cleavage. Eur J Immunol. 1994;24:2725–2731.
   PubMed Web of Science ®Google Scholar
• Jung S, Toyka KV, Hartung HP. Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in lewis rats. Neurosci Lett. 1995;200:167–170.
   PubMed Web of Science ®Google Scholar
• Créange A. A role for interferon-beta in Guillain-Barré syndrome? BioDrugs. 2000;14:1–11.
   PubMed Web of Science ®Google Scholar
• Zou LP, Ma DH, Wei L, et al. IFN-beta suppresses experimental autoimmune neuritis in Lewis rats by inhibiting the migration of inflammatory cells into peripheral nervous tissue. J Neurosci Res. 1999;56:123–130.
   PubMed Web of Science ®Google Scholar
• Pritchard J, Gray IA, Idrissova ZR, et al. A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome. Neurology. 2003;61:1282–1284.
   PubMed Web of Science ®Google Scholar
• Bensa S, Hadden RD, Hahn A, et al. Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barré syndrome: a pilot study. Eur J Neurol. 2000;7:423–426.
   PubMed Web of Science ®Google Scholar
• Frith JC, Mönkkönen J, Auriola S, et al. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum. 2001;44:2201–2210.
   PubMed Web of Science ®Google Scholar
• Katzav A, Bina H, Aronovich R, et al. Treatment for experimental autoimmune neuritis with clodronate (bonefos). Immunol Res. 2013;56:334–340.
   PubMed Web of Science ®Google Scholar
• Kieseier BC, Lehmann HC, Meyer Zu Hörste G. Autoimmune diseases of the peripheral nervous system. Autoimmun Rev. 2012;11:191–195.
   PubMed Web of Science ®Google Scholar
• Ibrahim H, Dimachkie MM, Shaibani A. A review: the use of rituximab in neuromuscular diseases. J Clin Neuromuscul Dis. 2010;12:91–102.
   PubMedGoogle Scholar
• Ostronoff F, Perales M-A, Stubblefield MD, et al. Rituximab-responsive Guillain-Barré syndrome following allogeneic hematopoietic SCT. Bone Marrow Transplant. 2008;42:71–72.
   PubMed Web of Science ®Google Scholar
• Jaso R, Sierra M, Calleja J, et al. Guillain-Barré syndrome after rituximab in a patient with idiopathic thombocytopenic purpura: a causal association? J Neurol. 2010;257:488–489.
   PubMed Web of Science ®Google Scholar
• Carmona A, Alonso JD, de las Heras M, et al. Guillain-Barre syndrome in a patient with diffuse large B-cell lymphoma, and rituximab maintenance therapy. An association beyond anecdotal evidence? Clin Transl Oncol. 2006;8:764–766.
   PubMedGoogle Scholar
• Terenghi F, Ardolino G, Nobile-Orazio E. Guillain-Barré syndrome after combined CHOP and rituximab therapy in non-hodgkin lymphoma. J Peripher Nerv Syst. 2007;12:142–143.
   PubMed Web of Science ®Google Scholar
• Cyclophosphamide Tablets, USP [Internet]. FDA. 2012 [cited 2017 Oct 30] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/012141s089lbl.pdf
   Google Scholar
• Rosen AD, Vastola EF. Clinical effects of cyclophosphamide in Guillain-Barré polyneuritis. J Neurol Sci. 1976;30:179–187.
   PubMed Web of Science ®Google Scholar
• Mangano K, Dati G, Quattrochi C, et al. Preventive and curative effects of cyclophosphamide in an animal model of Guillain Barrè syndrome. J Neuroimmunol. 2008;196:107–115.
   PubMed Web of Science ®Google Scholar
• Garssen MPJ, Van Koningsveld R, van Doorn PA, et al. Treatment of Guillain-Barré syndrome with mycophenolate mofetil: a pilot study. J Neurol Neurosurg Psychiatry. 2007;78:1012–1013.
   PubMed Web of Science ®Google Scholar
• Berciano J, Sedano MJ, Pelayo-Negro AL, et al. Proximal nerve lesions in early Guillain–barré syndrome: implications for pathogenesis and disease classification. J Neurol. 2017;264:221–236.
   PubMed Web of Science ®Google Scholar
• Sederholm BH. Treatment of acute immune-mediated neuropathies: guillain-Barré syndrome and clinical variants. Semin Neurol. 2010;30:365–372.
   PubMed Web of Science ®Google Scholar
• van den Berg B, Walgaard C, Drenthen J, et al. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10:469–482.
   PubMed Web of Science ®Google Scholar
• Chalela JA. Pearls and pitfalls in the intensive care management of Guillain-Barré syndrome. Semin Neurol. 2001;21:399–405.
   PubMed Web of Science ®Google Scholar
• Farcas P, Avnun L, Frisher S, et al. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome. Lancet. 1997;350:1747.
   PubMed Web of Science ®Google Scholar
• Thivakaran T, Gamage R, Gooneratne IK. Treatment-related fluctuation in Guillain-Barre syndrome. J Neurosci Rural Pract. 2011;2:168–170.
   PubMedGoogle Scholar
• Dimachkie MM, Barohn RJ. Guillain-Barré syndrome and variants. Neurol Clin. 2013;31:491–510.
   PubMed Web of Science ®Google Scholar
• Donofrio PD. Guillain-Barré syndrome. Continuum. 2017;23:1295–1309.
   PubMedGoogle Scholar
• Nagashima T, Koga M, Odaka M, et al. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Arch Neurol. 2007;64:1519–1523.
   PubMed Web of Science ®Google Scholar
• Mori M, Kuwabara S, Fukutake T, et al. Clinical features and prognosis of Miller Fisher syndrome. Neurology. 2001;56:1104–1106.
   PubMed Web of Science ®Google Scholar